Together, these results reveal a novel mechanism controlling SET degradation and ER‐α action in breast cancer cells and suggest that TRIM4 is a promising target for efforts to increase breast cancer cell sensitivity to endocrine therapy. Here, ESR1 is linked to breast carcinoma.